• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy

    12/29/25 8:22:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials
    Get the next $NITO alert in real time by email

    Neve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, today announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. ("Solterra"). Key milestones in Germany and Italy have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality.

    Key Investor Highlights

    • Permitting Risk Reduced: Strong progress with zero objections in Germany's public consultation and formal planning submissions in Italy, delivering enhanced visibility to approvals.
    • Over $1.69 Million in Value Creation: Strategic renegotiation in Germany optimizes returns through disciplined, capital-efficient moves.
    • High-Upside Monetization Flexibility: Italian battery storage projects primed for value realization in H2 2026, with options for sale or build-and-operate based on partner strategy.

    Germany Update: on track for Q3 2026 approval with savings secured

    • The flagship German project is advancing swiftly, nearing completion of its first public consultation round with no objections or material changes requested to date—a powerful signal of strong regulatory and community support.
    • Submission of the draft zoning plan for the final consultation is slated for late January, post-holidays. Current timelines point to final approval in Q3 2026, keeping the project firmly on its path.
    • In a demonstration of proactive value optimization, Solterra has indicated that an amendment to the development agreement was executed last week. Solterra will receive approximately €280,000 in advance funding to fuel faster progress, in exchange for a €11,000 per MW reduction in development fees- delivering project-level savings exceeding $1.69 million.
    • This capital-efficient transaction underscores N2OFF's focus on maximizing returns while accelerating high-potential assets.

    Italy Update: formal submissions mark key milestone toward H2 2026 potential approvals

    In late November, planning applications for the Sicilian battery storage projects were formally submitted.

    These projects are strongly de-risked with:

    • Secured, binding grid connection capacity

    • Preliminary land agreements (finalized upon permits)

    • Completion of extensive preparatory planning over six months

    Absent material objections, planning approvals are targeted for H2 2026. At that stage, N2OFF will assess optimal value realization paths—project sale or construction and operation—aligned with strategic partner decisions.



    About N2OFF Inc:

    N2OFF is a cleantech company mainly engaged in EU based solar assets using the RTB (Ready to Build ) business model. N2OFF is currently the lead investor in four solar projects in three different EU countries, all of which were introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

    N2OFF also holds 100% in MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family.

    In addition, N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatments for fruits and vegetables, aiming to control and prevent pathogen contamination. For more information on Save Foods Ltd. visit our website: www.n2off.com.

    Forward-looking Statements:

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties including the success of our collaboration with Solterra Energy Ltd., entry into future projects, our ability to successfully enter the solar PV sector, the profitability of such industry, and the potential added value of the increased capacity. Actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including market conditions as well as those discussed under the heading "Risk Factors" in N2OFF's Annual Report on Form 10-K filed with the SEC on March 31, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

    Investor Relations Contact:

    Michal Efraty

    [email protected]



    Primary Logo

    Get the next $NITO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NITO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NITO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company

    New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. ("Nexentis") and change in the trading symbol of the Company to "NXTS" on the Nasdaq Capital Market. The name change and the symbol change will take effect on the Nasdaq Capital Market on

    2/25/26 8:30:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

    MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑infl

    2/12/26 7:25:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

    Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induce

    2/2/26 8:05:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    SEC Filings

    View All

    SEC Form PRE 14A filed by N2OFF Inc.

    PRE 14A - Nexentis Technologies Inc. (0001789192) (Filer)

    3/2/26 7:29:06 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Nexentis Technologies Inc. (0001789192) (Filer)

    2/26/26 4:17:11 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    N2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

    8-K - N2OFF, Inc. (0001789192) (Filer)

    2/25/26 9:30:46 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rosenbloom Ronen bought 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    12/26/24 7:42:11 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    2/11/26 4:05:31 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    2/11/26 4:05:36 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    2/11/26 4:05:33 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Financials

    Live finance-specific insights

    View All

    N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company

    New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. ("Nexentis") and change in the trading symbol of the Company to "NXTS" on the Nasdaq Capital Market. The name change and the symbol change will take effect on the Nasdaq Capital Market on

    2/25/26 8:30:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    N2OFF Announces Strategic Initiatives Intended to Maximize Shareholder Value

    Neve Yarak, Israel, Oct. 02, 2024 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ (NASDAQ:NITO) (FSE:80W) ("N2OFF" or the "Company"), a clean tech company engaged in sustainable solutions for the energy and agri-tech industries, announced today key strategic initiatives approved by its board of directors (the "Board") that are intended to increase shareholder value. Key Highlights of the Board's Initiatives Spin-off of cleantech activities: N2OFF is considering pursuing a potential spin-off of its cleantech operations - NTWO OFF Ltd. and Save Foods Ltd. – into a separate publicly traded company with the intention of listing that spin-off company on a national exchange. In connection with the potential

    10/2/24 8:30:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials